cortistatin B | 882976-96-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: cortistatin B
• 英文别名: (1S,2R,4S,5S,6R,12R,13R,14S,16R)-14-(dimethylamino)-5-isoquinolin-7-yl-6-methyl-19-oxapentacyclo[14.2.1.01,9.02,6.011,16]nonadeca-8,10-diene-4,12,13-triol
• CAS: 882976-96-7
• 化学式: C₃₀H₃₆N₂O₄
• 分子量: 488.6
• InChiKey: UOILBRZCKBLNDS-KMWHWPCOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  36
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  86
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• CORTISTATIN ANALOGUES AND SYNTHESES THEREOF
  申请人：Flyer Alec Nathanson

  公开号：US20110190323A1

  公开（公告）日：2011-08-04

  The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: I and salts thereof, wherein R 1 , R 2 , R 3 , R 4 , n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.
• CORTISTATIN ANALOGUES AND SYNTHESES THEROF
  申请人：President and Fellows of Harvard College

  公开号：US20150111921A1

  公开（公告）日：2015-04-23

  The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: I and salts thereof, wherein R 1 , R 2 , R 3 , R 4 , n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.
• TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH CORTISTATIN DERIVATIVES
  申请人：President and Fellows of Harvard College

  公开号：US20180135134A1

  公开（公告）日：2018-05-17

  A method for the targeted selection and treatment of patients with a tumor or cancer, comprising (i) determining whether the patient has a RUNX1 pathway impairment; and if so (ii) administering an effective amount of a cortistatin or its pharmaceutically acceptable salt or oxide, optionally in a pharmaceutically acceptable composition.
• US9127019B2
  申请人：——

  公开号：US9127019B2

  公开（公告）日：2015-09-08
• US9714255B2
  申请人：——

  公开号：US9714255B2

  公开（公告）日：2017-07-25